DD295992A5 - Kontrastmittel - Google Patents

Kontrastmittel Download PDF

Info

Publication number: DD295992A5
Authority: DD; German Democratic Republic
Prior art keywords: contrast agent; contrast; sodium; contrast agents; sodium ion
Prior art date: 1989-03-17

Application number

DD90338762A

Other languages

German (de)

English (en)

Inventor

Torsten Almen

Lars Baath

Audun Oksendal

Original Assignee

��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-17

Filing date

1990-03-15

Publication date

1991-11-21

1990-03-15 Application filed by ��@��k�� filed Critical ��@��k��

1991-11-21 Publication of DD295992A5 publication Critical patent/DD295992A5/de

Links

239000002872 contrast media Substances 0.000 title claims abstract description 118
229910001415 sodium ion Inorganic materials 0.000 claims abstract description 59
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 6
239000011734 sodium Substances 0.000 claims description 18
229940039231 contrast media Drugs 0.000 claims description 9
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
150000001768 cations Chemical class 0.000 claims description 8
229910052708 sodium Inorganic materials 0.000 claims description 8
239000008365 aqueous carrier Substances 0.000 claims description 3
229960004359 iodixanol Drugs 0.000 claims description 3
NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 3
BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical group CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims description 2
239000006185 dispersion Substances 0.000 claims description 2
229960000554 metrizamide Drugs 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
230000001256 tonic effect Effects 0.000 claims 1
210000002216 heart Anatomy 0.000 abstract description 17
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract description 11
229910052740 iodine Inorganic materials 0.000 abstract description 10
239000011630 iodine Substances 0.000 abstract description 10
-1 Non-ionic Substances 0.000 abstract description 5
230000006872 improvement Effects 0.000 abstract description 2
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
239000011780 sodium chloride Substances 0.000 description 19
230000008602 contraction Effects 0.000 description 18
210000003743 erythrocyte Anatomy 0.000 description 18
230000000694 effects Effects 0.000 description 14
150000002500 ions Chemical class 0.000 description 13
230000002776 aggregation Effects 0.000 description 11
238000004220 aggregation Methods 0.000 description 11
239000000243 solution Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 10
238000001802 infusion Methods 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
230000009467 reduction Effects 0.000 description 8
206010020772 Hypertension Diseases 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical group OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
239000011575 calcium Substances 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
229960004537 ioversol Drugs 0.000 description 6
208000003663 ventricular fibrillation Diseases 0.000 description 6
230000001988 toxicity Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 3
230000002411 adverse Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
238000003384 imaging method Methods 0.000 description 3
238000011835 investigation Methods 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
238000002583 angiography Methods 0.000 description 2
210000000709 aorta Anatomy 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002586 coronary angiography Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229960001025 iohexol Drugs 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
210000000663 muscle cell Anatomy 0.000 description 2
210000004165 myocardium Anatomy 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000001603 reducing effect Effects 0.000 description 2
239000002904 solvent Substances 0.000 description 2
CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
241001608638 Nycteribiinae Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
108010023197 Streptokinase Proteins 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000007321 biological mechanism Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000000746 body region Anatomy 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000022900 cardiac muscle contraction Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
229960005423 diatrizoate Drugs 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
230000010339 dilation Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000004217 heart function Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000000297 inotrophic effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000002611 ionic contrast media Substances 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002405 nuclear magnetic resonance imaging agent Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
238000009877 rendering Methods 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000012800 visualization Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound

Landscapes

Health & Medical Sciences (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Liquid Crystal (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Devices For Indicating Variable Information By Combining Individual Elements (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Compositions Of Macromolecular Compounds (AREA)
Ultra Sonic Daignosis Equipment (AREA)
Lubricants (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Steroid Compounds (AREA)

DD90338762A 1989-03-17 1990-03-15 Kontrastmittel DD295992A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898906130A GB8906130D0 (en)	1989-03-17	1989-03-17	Compositions

Publications (1)

Publication Number	Publication Date
DD295992A5 true DD295992A5 (de)	1991-11-21

Family

ID=10653498

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90338762A DD295992A5 (de)	1989-03-17	1990-03-15	Kontrastmittel

Country Status (32)

Country	Link
US (1)	US5366722B1 (tr)
EP (2)	EP0463013A1 (tr)
JP (1)	JP2977045B2 (tr)
KR (1)	KR920700701A (tr)
CN (1)	CN1057703C (tr)
AT (1)	ATE123954T1 (tr)
AU (1)	AU638235B2 (tr)
BG (1)	BG60951B1 (tr)
CA (1)	CA2046886A1 (tr)
CZ (1)	CZ281381B6 (tr)
DD (1)	DD295992A5 (tr)
DE (1)	DE69020208T2 (tr)
DK (1)	DK0390242T3 (tr)
EG (1)	EG19431A (tr)
ES (1)	ES2073505T3 (tr)
FI (1)	FI914337A7 (tr)
GB (1)	GB8906130D0 (tr)
GR (1)	GR3017133T3 (tr)
HU (1)	HU206835B (tr)
IE (1)	IE67885B1 (tr)
IL (1)	IL93752A (tr)
JO (1)	JO1619B1 (tr)
NO (1)	NO302064B1 (tr)
NZ (1)	NZ232954A (tr)
OA (1)	OA09392A (tr)
PT (1)	PT93471B (tr)
RO (1)	RO112246B1 (tr)
RU (1)	RU2088261C1 (tr)
TR (1)	TR25111A (tr)
WO (1)	WO1990011094A1 (tr)
YU (1)	YU47911B (tr)
ZA (1)	ZA902052B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8919929D0 (en) *	1989-09-04	1989-10-18	Nycomed As	Compositions
US5614638A (en) *	1989-11-29	1997-03-25	Bracco International B.V.	Nonionic radiographic contrast agents
US5869024A (en) *	1989-11-29	1999-02-09	Bracco International B.V.	Methods and compositions for using non-ionic contrast agents to reduce the risk of clot formation in diagnostic procedures
RU2098131C1 (ru)	1990-03-09	1997-12-10	Нюкомед Имагинг А.С.	Контрастная среда и способ ее получения
GB9020091D0 (en) *	1990-09-14	1990-10-24	Nycomed As	Contrast media
US5527926A (en) *	1990-11-26	1996-06-18	Bracco International B.V.	Methods and compositions for using non-ionic contrast agents to reduce the risk of clot formation in diagnostic procedures
US5278311A (en) *	1992-06-05	1994-01-11	E. R. Squibb & Sons, Inc.	Nonionic radiographic contrast agents
IT1256248B (it) *	1992-12-24	1995-11-29	Bracco Spa	Formulazioni iniettabili acquose per radiodiagnostica comprendenti miscele di composti aromatici iodurati utili come agenti opacizzanti ai raggi x
DE4406474A1 (de) *	1994-02-23	1995-08-24	Schering Ag	Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel
GB9419203D0 (en) *	1994-09-23	1994-11-09	Nycomed Innovation Ab	Contrast media
GB9419206D0 (en) *	1994-09-23	1994-11-09	Nycomed Innovation Ab	Contrast media
IL124676A0 (en) *	1996-01-25	1998-12-06	Schering Ag	Improved concentrated injection and infusion solutions for intravenous use
EP0885616A1 (de) *	1997-06-20	1998-12-23	Schering Aktiengesellschaft	Verwendung von intravenösen Kontrastmitteln sowie Vorrichtungen für die Projektionsmammographie
AU2010311478B2 (en)	2009-10-29	2015-09-24	Ge Healthcare As	Diagnostic composition comprising plasma cations having superior safety profile
EP2550022B1 (en) *	2010-03-23	2020-12-09	GE Healthcare AS	Preparation of stabilised x-ray diagnostic composition
SG11201507964TA (en) *	2013-03-27	2015-10-29	Ge Healthcare As	Method and reagent for preparing a diagnostic composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2909439A1 (de) *	1979-03-08	1980-09-18	Schering Ag	Neue nichtionische roentgenkontrastmittel
DE2928417A1 (de) *	1979-07-12	1981-01-29	Schering Ag	Trijodierte basen
DE3038853A1 (de) *	1980-10-10	1982-05-27	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue n-hydroxy-alkylierte dicarbonsaeure-bis-(3,5-dicarbamoyl-2,4,6-trijodanilide), deren herstellung und diese enthaltende roentgenkonstrastmittel (ii)
US4957939A (en) *	1981-07-24	1990-09-18	Schering Aktiengesellschaft	Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4663166A (en) *	1984-06-22	1987-05-05	Veech Richard L	Electrolyte solutions and in vivo use thereof
ATE72398T1 (de) *	1984-06-22	1992-02-15	Richard L Veech	Polyanionische materialien enthaltende elektrolytloesungen.
US4863714A (en) *	1987-02-05	1989-09-05	Cook Imaging Corporation	Sterilization of compositions of limited stability
US5011925A (en) *	1989-03-09	1991-04-30	Mallinckrodt, Inc.	Morpholinoamido EDTA derivatives

1989
- 1989-03-17 GB GB898906130A patent/GB8906130D0/en active Pending
1990
- 1990-03-09 DE DE69020208T patent/DE69020208T2/de not_active Expired - Lifetime
- 1990-03-09 ES ES90200580T patent/ES2073505T3/es not_active Expired - Lifetime
- 1990-03-09 HU HU902356A patent/HU206835B/hu not_active IP Right Cessation
- 1990-03-09 JP JP2504207A patent/JP2977045B2/ja not_active Expired - Lifetime
- 1990-03-09 RO RO148301A patent/RO112246B1/ro unknown
- 1990-03-09 EP EP90904340A patent/EP0463013A1/en active Pending
- 1990-03-09 WO PCT/EP1990/000393 patent/WO1990011094A1/en not_active Ceased
- 1990-03-09 KR KR1019910701153A patent/KR920700701A/ko not_active Ceased
- 1990-03-09 RU SU5010018/14A patent/RU2088261C1/ru active
- 1990-03-09 DK DK90200580.0T patent/DK0390242T3/da active
- 1990-03-09 AT AT90200580T patent/ATE123954T1/de not_active IP Right Cessation
- 1990-03-09 EP EP90200580A patent/EP0390242B1/en not_active Expired - Lifetime
- 1990-03-09 AU AU51854/90A patent/AU638235B2/en not_active Ceased
- 1990-03-09 CA CA002046886A patent/CA2046886A1/en not_active Withdrawn
- 1990-03-09 FI FI914337A patent/FI914337A7/fi not_active Application Discontinuation
- 1990-03-14 IL IL9375290A patent/IL93752A/en not_active IP Right Cessation
- 1990-03-14 YU YU50390A patent/YU47911B/sh unknown
- 1990-03-15 DD DD90338762A patent/DD295992A5/de not_active IP Right Cessation
- 1990-03-15 CZ CS901257A patent/CZ281381B6/cs unknown
- 1990-03-16 TR TR90/0280A patent/TR25111A/tr unknown
- 1990-03-16 PT PT93471A patent/PT93471B/pt not_active IP Right Cessation
- 1990-03-16 IE IE97090A patent/IE67885B1/en not_active IP Right Cessation
- 1990-03-16 NZ NZ232954A patent/NZ232954A/en unknown
- 1990-03-16 ZA ZA902052A patent/ZA902052B/xx unknown
- 1990-03-17 CN CN90101396A patent/CN1057703C/zh not_active Expired - Lifetime
- 1990-03-17 JO JO19901619A patent/JO1619B1/en active
- 1990-03-18 EG EG17490A patent/EG19431A/xx active
1991
- 1991-08-19 OA OA60064A patent/OA09392A/xx unknown
- 1991-09-16 NO NO913641A patent/NO302064B1/no not_active IP Right Cessation
- 1991-10-16 BG BG95330A patent/BG60951B1/bg unknown
1993
- 1993-11-24 US US08156998 patent/US5366722B1/en not_active Expired - Lifetime
1995
- 1995-08-16 GR GR950402252T patent/GR3017133T3/el unknown

Also Published As

Publication number	Publication date
EP0390242B1 (en)	1995-06-21
ZA902052B (en)	1990-12-28
US5366722B1 (en)	2000-03-14
JO1619B1 (en)	1991-11-27
DE69020208T2 (de)	1996-03-21
YU47911B (sh)	1996-05-20
HUT59015A (en)	1992-04-28
DE69020208D1 (de)	1995-07-27
FI914337A0 (fi)	1991-09-16
AU5185490A (en)	1990-10-22
RO112246B1 (ro)	1997-07-30
HU902356D0 (en)	1991-12-30
ES2073505T3 (es)	1995-08-16
NO302064B1 (no)	1998-01-19
CA2046886A1 (en)	1990-09-18
FI914337A7 (fi)	1991-09-16
US5366722A (en)	1994-11-22
IL93752A (en)	1994-11-11
ATE123954T1 (de)	1995-07-15
WO1990011094A1 (en)	1990-10-04
GR3017133T3 (en)	1995-11-30
CZ281381B6 (cs)	1996-09-11
NO913641L (no)	1991-09-16
BG60951B1 (en)	1996-07-31
PT93471B (pt)	1996-03-29
CN1057703C (zh)	2000-10-25
JP2977045B2 (ja)	1999-11-10
EG19431A (en)	1995-10-31
IL93752A0 (en)	1990-12-23
YU50390A (sh)	1994-01-20
EP0463013A1 (en)	1992-01-02
GB8906130D0 (en)	1989-05-04
NO913641D0 (no)	1991-09-16
DK0390242T3 (da)	1995-08-14
IE67885B1 (en)	1996-05-01
CN1045528A (zh)	1990-09-26
HU206835B (en)	1993-01-28
AU638235B2 (en)	1993-06-24
BG95330A (bg)	1993-12-24
NZ232954A (en)	1992-04-28
RU2088261C1 (ru)	1997-08-27
KR920700701A (ko)	1992-08-10
IE900970L (en)	1990-09-17
JPH04504114A (ja)	1992-07-23
EP0390242A1 (en)	1990-10-03
TR25111A (tr)	1992-11-01
PT93471A (pt)	1990-11-07
OA09392A (en)	1992-09-15

Legal Events

Date	Code	Title	Description
1999-01-07	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE69121562T2 (de)	1997-01-16	Kontrastmittel enthaltend einen nicht-ionischen kontrast Wirkstoff und Sodium und Kalzium Sälze
DD295992A5 (de)	1991-11-21	Kontrastmittel
DE69006805T2 (de)	1994-06-01	Kontrastmittel.
HK1003563B (en)	1998-10-30	Contrast medium containing a non-ionic contrast agent and sodium and calcium salts
EP0994729B1 (de)	2002-12-18	Verwendung von intravenösen kontrastmitteln für die projektionsmammographie
DE1951769A1 (de)	1970-07-16	Pharmazeutische Suspension und Stabilisierungsverfahren
DE4426438A1 (de)	1996-02-01	Verwendung von Chelaten als Röntgenkontrastmittel
DE4426439C1 (de)	1996-02-29	Kontrastmittel zur Darstellung der Leber
DE3406834C2 (de)	1997-06-12	Verwendung von Perfluorbromalkylethern als Röntgenkontrastmittel
AU645544C (en)	1998-08-20	Contrast media
DE3018515A1 (de)	1980-12-04	Roentgenkontrastmittel
DE1767739A1 (de)	1971-09-23	Roentgenkontrastmittel fuer die Sichtbarmachung der Koerperhoehlen,welche die Cerebrospinalfluessigkeit enthalten